









市场行情
/
股票
/
nasdaq-kpti
/

Karyopharm Therapeutics Inc

KPTI

6.940USD

+0.570+8.95%

收盘 12/19, 16:00（美东）报价延迟15分钟

60.39M总市值

亏损市盈率 TTM



Karyopharm Therapeutics Inc

6.940

+0.570+8.95%

概览公司财务分析

概览

公司

财务

分析

关于 Karyopharm Therapeutics Inc 公司

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Karyopharm Therapeutics Inc简介



公司代码KPTI

公司名称Karyopharm Therapeutics Inc

上市日期Nov 06, 2013

CEOPaulson (Richard A)

员工数量279

证券类型Ordinary Share

年结日Nov 06

公司地址85 Wells Avenue

城市NEWTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02459

电话16176580600

网址https://karyopharm.com/

公司代码KPTI

上市日期Nov 06, 2013

CEOPaulson (Richard A)

Karyopharm Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Michael Mano, J.D.

Senior Vice President, General Counsel, Secretary

55.93K

+355.57%

Mr. Stuart Poulton

Executive Vice President, Chief Development Officer

48.29K

+460.88%

Dr. Reshma Rangwala, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

7.24K

+8.01%

Mr. Barry E. Greene

Lead Independent Director

907.00

Ms. Sohanya Cheng

Executive Vice President, Chief Commercial Officer

Mr. Garen G. Bohlin

Independent Director

Mr. Chen Schor, CPA

Independent Director

Mr. Richard A. Paulson

President, Chief Executive Officer, Director

Mr. Brendan Strong

Senior Vice President - Investor Relations and Corporate Communications

Ms. Lori Macomber, CPA

Executive Vice President, Chief Financial Officer, Treasurer

名称

名称/职务

职务

持股

持股变动

Mr. Michael Mano, J.D.

Senior Vice President, General Counsel, Secretary

55.93K

+355.57%

Mr. Stuart Poulton

Executive Vice President, Chief Development Officer

48.29K

+460.88%

Dr. Reshma Rangwala, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

7.24K

+8.01%

Mr. Barry E. Greene

Lead Independent Director

907.00

Ms. Sohanya Cheng

Executive Vice President, Chief Commercial Officer

Mr. Garen G. Bohlin

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

T. Rowe Price Investment Management, Inc.

13.51%

Opaleye Management Inc.

5.57%

J. Wood Capital Advisors LLC

4.60%

Adage Capital Management, L.P.

2.47%

The Vanguard Group, Inc.

2.39%

其他

71.45%

持股股东

占比

T. Rowe Price Investment Management, Inc.

13.51%

Opaleye Management Inc.

5.57%

J. Wood Capital Advisors LLC

4.60%

Adage Capital Management, L.P.

2.47%

The Vanguard Group, Inc.

2.39%

其他

71.45%

股东类型

持股股东

占比

Investment Advisor

18.95%

Hedge Fund

9.84%

Corporation

4.60%

Investment Advisor/Hedge Fund

2.40%

Individual Investor

2.32%

Venture Capital

0.92%

Research Firm

0.71%

Bank and Trust

0.06%

其他

60.18%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

251

4.11M

24.14%

-1.36M

2025Q2

284

4.20M

48.66%

-1.75M

2025Q1

308

4.25M

49.43%

-1.53M

2024Q4

324

4.68M

55.67%

-1.51M

2024Q3

341

4.98M

60.06%

-2.16M

2024Q2

356

5.56M

67.54%

-2.08M

2024Q1

352

5.60M

72.46%

-1.99M

2023Q4

354

5.60M

73.31%

-2.02M

2023Q3

365

5.88M

77.33%

-1.69M

2023Q2

380

6.19M

81.48%

-2.04M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

T. Rowe Price Investment Management, Inc.

728.77K

8.4%

+589.12K

+421.87%

Jun 30, 2025

J. Wood Capital Advisors LLC

458.13K

5.28%

Apr 10, 2025

Adage Capital Management, L.P.

421.32K

4.86%

Jun 30, 2025

The Vanguard Group, Inc.

518.27K

5.98%

+7.97K

+1.56%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

184.85K

2.13%

-3.16K

-1.68%

Jun 30, 2025

Catalio Capital Management, LP

146.01K

1.68%

-9.61K

-6.17%

Jun 30, 2025

Avidity Partners Management LP

134.57K

1.55%

Jun 30, 2025

Marshall Wace LLP

128.45K

1.48%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.01%

Global X Russell 2000 Covered Call ETF

Invesco NASDAQ Future Gen 200 ETF

Fidelity Enhanced Small Cap ETF

Goldman Sachs ActiveBeta US Small Cap Equity ETF

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

ProShares UltraPro Russell2000

Proshares Ultra Russell 2000

iShares Russell 2000 Growth ETF

iShares Micro-Cap ETF

占比0.01%

Global X Russell 2000 Covered Call ETF

占比0%

Invesco NASDAQ Future Gen 200 ETF

占比0%

Fidelity Enhanced Small Cap ETF

占比0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0%

ProShares Hedge Replication ETF

占比0%

iShares Russell 2000 ETF

占比0%

ProShares UltraPro Russell2000

占比0%

Proshares Ultra Russell 2000

占比0%

iShares Russell 2000 Growth ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

公告日期

类型

比率

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

Feb 24, 2025

Merger

15→1

常见问题

Karyopharm Therapeutics Inc的前五大股东是谁？



Karyopharm Therapeutics Inc 的前五大股东如下：
T. Rowe Price Investment Management, Inc.持有股份：728.77K，占总股份比例：8.40%。
J. Wood Capital Advisors LLC持有股份：458.13K，占总股份比例：5.28%。
Adage Capital Management, L.P.持有股份：421.32K，占总股份比例：4.86%。
The Vanguard Group, Inc.持有股份：518.27K，占总股份比例：5.98%。
BlackRock Institutional Trust Company, N.A.持有股份：184.85K，占总股份比例：2.13%。